1. 3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience. (September 2015) Authors: Cadranel, J.; Cortot, A.; Lena, H.; Mennecier, B.; Do, P.; Dansin, E.; Mazieres, J.; Chouaid, C.; Perol, M.; Barlesi, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S616 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. (September 2015) Authors: Soria, J.C.; Goldman, J.W.; Wakelee, H.; Gadgeel, S.; Camidge, D.R.; Solomon, B.; Yu, H.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Perol, M.; Reckamp, K.; Varga, A.; Dziadziuszko, R.; Chouaid, C.; Cortot, A.; Do, P.; Moro-Sibilot, D.; Poudenx, M.; Sequist, L.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S637 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗